CytoMed Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow-97.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for GDTC is -97.38%. That is below the sector sector average of 11.85%. Investors often review this figure alongside CytoMed Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, GDTC currently prints -97.38% for ROE, while the sector average sits near 11.85%. That is roughly 921.6% below the sector mean. Large gaps often invite a closer look at CytoMed Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively CytoMed Therapeutics converts resources into returns. At -97.38%, GDTC may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting GDTC's ROE (-97.38%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
